Importance of vaccine action and availability and epidemic severity for delaying the second vaccine dose

Luděk Berec, René Levı́nský, Jakub Weiner, Martin Šmíd, Roman Neruda, Petra Vidnerová, Gabriela SuchopárováScientific 2022 · DOI

TL;DR

Should we delay the second COVID-19 vaccine dose to get more "first shots in arms," or stick to the manufacturer's schedule? This study uses three distinct epidemic models calibrated to the Czech Republic's 2021 rollout to show that the answer isn't universal—it depends heavily on whether the vaccine primarily stops infection or prevents death, the current severity of the epidemic, and the speed of the supply chain.

What Problem Does This Paper Address?

During the spring of 2021, many countries faced a logistical nightmare: high infection rates and low vaccine supplies. This sparked a heated debate over "dose-sparing" strategies—specifically, extending the interval between the first and second doses (e.g., from 21 to 42 days).

Proponents argued that partial protection for many is better than full protection for few. Critics worried about reduced efficacy and the potential for waning immunity. While early models attempted to settle this, they were often overly simplistic, ignoring the dynamic nature of an ongoing epidemic, real-world rollout constraints, and the specific biological "mode of action" of the vaccines. This paper seeks to provide a more robust, data-driven answer by modeling the complexities of the Czech Republic’s specific epidemic trajectory.

Methods

The researchers employed a "triangulation" approach, using three different epidemic models to ensure their findings weren't artifacts of a single mathematical framework:

  1. Model H (Deterministic/Compartmental): Focused on the flow of patients through hospitals and ICUs, categorized by four age cohorts.
  2. Model M (Agent-Based): A high-resolution simulation of 56,000 synthetic individuals connected by a realistic network of social contacts (work, home, school).
  3. Model F (Stochastic SEIR): A discrete-time model that explicitly accounts for "hidden" (undetected) infections and varies based on social contact restrictions and public "fear" levels.

Crucially, the authors didn't just look at "vaccine efficacy" as a single number. They modeled five distinct ways a vaccine can act: preventing infection, preventing symptoms, preventing hospitalization, preventing the need for ICU, and preventing death.

Datasets

The models were calibrated using real-world data from the Czech Republic:

  • Epidemiological Data: Time series of reported cases, hospitalizations, ICU admissions, and deaths provided by the Institute of Health Information and Statistics of the Czech Republic.
  • Sociological Data: Longitudinal surveys from PAQ Research regarding social contact reductions during various lockdown phases.
  • Vaccination Data: Actual rollout numbers from December 2020 to March 2021, including the rise of the Alpha (B.1.1.7) variant.

Key Insights and Ideas

  • The "Where" Matters: If a vaccine is highly effective at the beginning of the infection chain (preventing you from getting infected at all), sticking to the 21-day schedule is often better. You want to reach "full" protection quickly to break transmission chains.
  • The "Safety Net" Strategy: If the vaccine is primarily effective at the end of the chain (preventing death or ICU admission), delaying the second dose is superior. In this scenario, the first dose acts as a broad "safety net" that reduces mortality across a larger portion of the population.
  • Multiplicative Effects: Vaccine actions at different stages (e.g., stopping symptoms vs. stopping death) are multiplicative, not additive. This means a small change in early-stage efficacy can have a massive downstream impact on total deaths.
  • Contextual Sensitivity: The "correct" strategy shifts based on the environment. A severe epidemic with a slow vaccine supply strongly favors delaying the second dose. Conversely, a mild epidemic with a fast supply chain favors the original 21-day schedule.

Key Results

The study used COVID-19-related deaths averted as the primary metric for success.

  • Delaying is better when: The vaccine prevents severe symptoms/death, the epidemic is severe, and supply is low. In these "extreme" scenarios, delaying the second dose was beneficial across almost any plausible level of vaccine efficacy.
  • Sticking to 21 days is better when: The vaccine prevents infection/symptoms, the epidemic is mild, and supply is sufficient.
  • Waning Immunity: The authors tested the impact of immunity waning within the 6-week window. They found that while waning does make the 42-day delay slightly less attractive, it doesn't fundamentally change the results because the 6-week window is too short for significant decline.

Limitations and Future Work

The authors acknowledge several limitations:

  • Variant Specificity: The study was calibrated to the Alpha variant. Newer variants like Delta or Omicron, which have different transmission rates and "immune escape" capabilities, might yield different results.
  • Geographic Constraints: The models rely on the specific social contact structures and healthcare capacity of the Czech Republic.
  • Long-term Waning: The study only looked at a 42-day delay. It does not address the much longer delays (3-4 months) adopted by some countries (like the UK), where long-term immunity waning becomes a much larger factor.

Future research could apply this multi-model approach to newer variants and explore the trade-offs of even longer dose intervals in the context of booster shots.

Summary updated

Abstract

Following initial optimism regarding potentially rapid vaccination, delays and shortages in vaccine supplies occurred in many countries during spring 2021. Various strategies to counter this gloomy reality and speed up vaccination have been set forth, of which the most popular has been to delay the second vaccine dose for a longer period than originally recommended by the manufacturers. Controversy has surrounded this strategy, and overly simplistic models have been developed to shed light on this issue. Here we use three different epidemic models, all accounting for then actual COVID-19 epidemic in the Czech Republic, including the real vaccination rollout, to explore when delaying the second vaccine dose by another 3 weeks from 21 to 42 days is advantageous. Using COVID-19-related deaths as a quantity to compare various model scenarios, we find that the way of vaccine action at the beginning of the infection course (preventing infection and symptoms appearance), mild epidemic and sufficient vaccine supply rate call for the original inter-dose period of 21 days regardless of vaccine efficacy. On the contrary, for the vaccine action at the end of infection course (preventing severe symptoms and death), severe epidemic and low vaccine supply rate, the 42-day inter-dose period is preferable, at any plausible vaccine efficacy.
BibTeX
@inproceedings{berec2022importance,
  author = {Luděk Berec and René Levı́nský and Jakub Weiner and Martin Šmíd and Roman Neruda and Petra Vidnerová and Gabriela Suchopárová},
  title = {{Importance of vaccine action and availability and epidemic severity for delaying the second vaccine dose}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41598-022-11250-4},
}
Figure